Searched for
ANDAS ACQUISITION
Senores Pharma to acquire 14 ANDAs from Dr Reddy's LaboratoriesSenores Pharmaceuticals of Gujarat has signed an agreement to acquire 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories. Th...- Rubicon Research files DRHP for Rs 1,085 crore IPORubicon Research IPO News: The company’s IPO comprises a fresh issue of up to ₹500 crore and an offer for sale of up to ₹ 585 crore by the ...
- Glenmark Pharmaceuticals acquires certain OTC drugs from Wockhardt in US"The over-the-counter market has long been an important segment of Glenmark's portfolio around the world. Our acquisition of these ANDAs re...
- Strides Pharma banks on acquired Endo portfolio for turnaround of its US businessOn August 6, 2021, Strides announced acquisition of an Endo manufacturing facility in the US along with a basket of ANDAs for $24.9 million...
- Strides Pharma says could take 3-4 qtrs for normalcy of US business hit price erosionThe company on Wednesday reported a net loss of Rs 168 crore in Q2FY22. In the H1FY22, Strides accumulated a net loss of Rs 376.6. Revenues...
- Strides Pharma Science to acquire Endo's manufacturing facility in US along with basket of ANDAsStrides said the facility at Chestnut Ridge, New York has an annual capacity of 2 billion units across semi- solids, liquids, nasal sprays ...
- Dr Reddy's acquires a portfolio of 42 ANDAs in USThese products will require to be technology transferred and could be launched within the next one to two years.
- Torrent Pharma buys US firm Bio-PharmTorrent Pharma said it plans further investments to expand the BPI facilities, including its research and development (R&D) capabilities, a...
- Zydus Healthcare buys 2 ANDAs from TevaThe company said these ANDAs have been acquired by its 100 per cent subsidiary, Zydus Worldwide DMCC and will be financed through the group...
- Neutral Dr Reddy's Laboratories, target Rs 3200: Motilal OswalTeva is divesting the portfolio as a pre-condition to close the Allergan deal (due to overlap). The acquisition of these ANDAs is contingen...
- Overweight Dr Reddy's Laboratories, target Rs 3600: JPMorganThe acquisition of ANDAs is contingent upon closing of Teva/Allergan transaction.
- Dr. Reddy’s buys eight ANDAs from Teva for $350 millionDr. Reddy’s said the acquisition of ANDAs is contingent on closing of the Teva generics transaction and approval by the US Federal Trade Co...
- Lupin completes acquisition of GAVIS PharmaThe acquisition enhances the company's scale in the US generic market and also broadens its pipeline in dermatology and controlled substanc...
- Lupin disappoints with Q1 nos; acquisition looks expensive; stock may correct: Mayuresh JoshiQ1 numbers were disappointing; acquisition looks expensive and, at the current level, Lupin stock also looks quite expensive to us, says Jo...
- Lupin looking to enter new product segments, geographies: MD Nilesh GuptaIn order to consolidate its business globally, the Mumbai-based firm has already inked various agreements in the previous fiscal.
- Lupin to beef up branded portfolio through alliances and strategic brand acquisitionsLupin is looking at strengthening its branded portfolio by creating alliances and eyeing strategic brand acquisitions in US markets in 2015...
- Sun Pharma plans expansion in US and large emerging marketsSun Pharmaceuticals Industries on Friday said it is open to acquisitions in both developed and emerging markets to fuel growth.
- Taro integration worries weigh on Sun Pharma investorsThe latest verdict of the Israeli Supreme Court will enable Sun Pharma to increase its stake in Taro to around 53 per cent.
- Granules looks to buy controlling stake in Chinese coHyderabad-based pharma firm Granules India is close to finalising a Rs 180-200-crore deal with a Chinese pharmaceutical company.
- Glenmark's US arm in $27m-deal with Paul CapitalThe US subsidiary of Glenmark Pharmaceuticals (Glenmark) has signed a $27m deal with Paul Capital Partners’ Royalty Fund.
Load More
